reviewed HS and nuclear grades were 90.9 and 21.1 %, respectively. HS correlated with OS (P = 0.043) but was not an independent prognostic factor in the multivariate analysis (P = 0.820). Tumor size, Fuhrman grade, and infiltration type were common independent prognostic factors for OS, CSS, and RFS. Conclusions This study revealed RCC outcomes in the era of cytokine treatment for metastasis. Central pathological review is an essential component of a multicenter study with long-term follow-up. Tumor size, Fuhrman grade, and infiltration type had much greater effects than HS on survival after curative nephrectomy.
Introduction
The incidence of renal cell carcinoma (RCC) is increasing; RCC accounts for approximately 3 % of all cancers among adults in Western countries, and its incidence is also increasing in Japan [1] . Although tumor staging (TNM), Fuhrman grade, and performance status (PS) are the most widely recognized prognostic indicators for RCC, easily available prognostic data that facilitate patient management on the basis of different mortality risks have been investi
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Cancer Control (UICC), which was published in 2009 [4] . Therefore, information from those earlier studies cannot be applied to current patient management. Also, it remains uncertain whether histological subtype (HS) is an independent prognostic indicator for RCC. To the best of our knowledge, only 5 studies have investigated the prognostic value of HS by pathological review [5] [6] [7] [8] [9] , and single pathologists performed 4 of these studies. Furthermore, to demonstrate the state of modern practice with regard to RCC outcomes, a multi-institutional study of patient data collected during a short period is mandatory. Therefore, in this study we attempted to collect data from 914 cases of RCC treated with potentially curative nephrectomy at 22 centers during a short period (6 years) and investigated the effects of anatomical and clinical factors, HS, and nuclear grades on survival on the basis of a central pathological review by 5 board-certified pathologists who specialized in renal neoplasm.
Patients and methods

Patients
We collected data for patients with histopathological diagnosis of RCC during original pathological evaluations at 22 urological centers in Japan between 1995 and 2000. To determine outcome for patients with RCC in 2000, we limited the data collection period to a relatively short duration of 6 years. The patients' clinical records were extracted from each institutional database. Each center was requested to conduct a follow-up mail or telephone survey to obtain survival data for more than 85 % of patients with RCC at 5 years post-diagnosis. Collected data included the TNM stage (AJCC/UICC, seventh edition), original histopathological diagnosis made at each institution, PS, overall survival (OS), cancer-specific survival (CSS), relapse-free survival (RFS), clinical symptoms, and laboratory test results. Data were labeled at the respective institutions and combined into a single database.
Pathological evaluation
To evaluate eligibility for this study, 2 representative hematoxylin and eosin (H&E) slides from each case were requested for central pathological review. The review board comprised 5 board-certified diagnostic pathologists specializing in urologic pathology, including 1 author (YM). Each pathologist assigned their interpretations in accordance with the Heidelberg classification of RCC (UICC Workshop 1997) [10] and the WHO classification (2004) [3] , and nuclear grade according to the Fuhrman system and the Japanese classification [11] . In addition, papillary subtype was divided into 2 categories, types 1 and 2 papillary RCC. Cases with discordant interpretations were reevaluated to obtain consensus on the HS and grade in pathology review committee meetings. The presence of coagulative tumor necrosis could not be evaluated because only 2 representative slides were available for review.
Statistical analysis
OS, CSS, and RFS curves were calculated by use of the Kaplan-Meier method. The log-rank test was used to evaluate the effects of patients' characteristics on OS, CSS, and RFS. To identify independent prognostic factors we performed a Cox proportional hazards regression analysis with backward elimination. The kappa statistic was used to measure agreement between the initial diagnosis and central pathology review. All statistical analysis was conducted by use of SAS, version 9.2 (SAS Institute, Cary, NC, USA), and a 2-sided P value of <0.05 was regarded as statistically significant.
Results
Patient population
A total of 914 cases of RCC treated with potentially curative nephrectomy (788 radical and 126 partial) against local tumors were collected; of these, 119 patients (13.0 %) developed recurrent disease. The median follow-up period for the 782 surviving patients was 89 months, and median survival was 47 months for the 132 patients who died during follow-up. Five cases (0.48 %) died within 1 month of nephrectomy as a result of complications or rapid RCC progression in advanced cases, and 27 cases (6.3 %) of pT1a, cN0M0 RCC (n = 431) recurred after curative nephrectomy.
Central pathology review
Of the 914 RCC cases diagnosed on the basis of the original histopathological evaluation at each institution, 678 were classified as clear cell, 3 Table 2b ). Two hundred and fifty-three and 100 cases diagnosed as G2 and G3 RCC by central pathology review had been originally diagnosed as G1. Overall concordance did not significantly differ among the institutions (P = 0.292).
HS and survival of RCC patients after potentially curative nephrectomy for local tumors
Five and 7-year OS for 814 RCC cases treated with curative nephrectomy were 92 and 87 %, respectively (Fig. 1a) , and the corresponding CSS and RFS were 96 and 93 and 88 and 85 %, respectively (Fig. 1b, c) . A total of 110 cases (93 clear, 6 papillary, 6 chromophobe, and 5 unclassified) from among 814 cases treated with curative nephrectomy experienced relapse during the follow-up period after curative nephrectomy. Five-year CSS and RFS after curative nephrectomy among pT1N0M0, pT2N0M0, and pT3N0M0 cases in this study were 99 and 96 %, 93 and 80 %, and 89 and 71 %, respectively. Two hundred and seventy-six cases received interferon-α as adjuvant therapy. Interferon-β did not improve OS (hazard ratio (HR) = 1.199; 95 % CI 0.839-1.714; P = 0.319), CSS (HR = 2.333; 95 % CI 1.405-3.874; P = 0.001), or RFS (HR = 2.428; 95 % CI 1.711-3.444; P < 0.001) in this study.
In univariate analysis, OS was associated with HS for 5 subtypes: clear, papillary type 1, papillary type 2, chromophobe, and unclassified (P = 0.043) ( Fig. 2a; Table 3) ; however, no association was found with the clear and non-clear subtypes (P = 0.170, Fig. 2b ). The lowest HR relative to the clear subtype was observed for chromophobe (0.62), followed by papillary type 1 (0.97), papillary type 2 (1.966), and unclassified subtype (2.426; Table 3 ).
OS was also associated with tumor size (P < 0.001; Fig. 2c ; Table 3 ), Fuhrman grade (P < 0.001), gender (P = 0.005), PS (P < 0.001), TNM stage (P < 0.001), preoperative hemoglobin (Hb) level (P = 0.004), platelet (Plt) count (P = 0.003), albumin (alb) level (P < 0.001), and C-reactive protein (CRP) level (P = 0.014); CSS and RFS were not associated with age, PS, Hb, alb, or Plt (data not shown). Fuhrman grade was a good prognostic indicator for the clear (P < 0.0001) and papillary histologic subtypes (P = 0.0389) but not the chromophobe subtype (P = 0.691), as reported elsewhere [12] .
We also performed multivariate analysis to identify the prognostic factors associated with OS, CSS, and RFS among RCC patients after potentially curative nephrectomy (Table 3) . Hb, Plt, alb, and CRP were only available for approximately half of the patients and were therefore not included in this analysis. The multivariate analysis indicated that only tumor size, Fuhrman grade, and infiltration type were common independent prognostic factors for OS, CSS, and RFS. Although gender was not directly related to age, female gender was a significant prognostic factor for OS (P < 0.001) but not for RFS (P = 0.080).
Discussion
We collected clinical data for 914 RCC patients treated with curative nephrectomy over a 6-year period beginning in 1995 and analyzed both clinical and histological data. The histological findings for these cases were re-evaluated by 5 pathologists. Most previous large outcome studies required a study period longer than a decade or international collaboration between institutions with different backgrounds to collect sufficient numbers of patients. In contrast, the results from this study seem to represent the true state of the art of RCC management during the era of the cytokine treatment for metastatic RCC (mRCC; circa 2000) in Japan. CSS in this study seemed superior to that reported in Western countries whereas RFS was similar [13] [14] [15] [16] . Fujii et al. also reported that CSS among Japanese patients with RCC was longer than that reported in Western countries for patients with identical Mayo Clinic stages, tumor sizes and grades, and necrosis (SSIGN) scores [17] . Naito et al. recently reported prolonged survival among mRCC patients in Japan compared with those in Western countries during the era of cytokine treatment, suggesting that lead time bias as a result of full medical tests and treatment coverage for all patients in the Japanese medical insurance system, genetic differences, or the use of non-recombinant interferon as immunotherapy might have led to better prognosis [18] . Therefore, the long CSS in our study might be the result of long survival of patients with metastatic RCC.
Several studies have reported better survival among female patients than among male patients after curative nephrectomy [19, 20] . In this study, significantly better OS was observed among female patients but not RFS. Survival analysis adjusted for estimated life expectancy would be necessary to understand the different RCC biological behavior between the genders.
The survival of RCC patients after curative nephrectomy did not significantly differ among the institutions after adjusting for gender, age, and tumor size (P = 0.082) and did not depend on the volumes of the institutions. This is probably because most Japanese urologists (both residents in training and specialized urologists) experience multiple transitions between institutions, thus enabling the rapid transmission of surgical skills to all institutions, and because Japanese public medical insurance provides equal coverage to all hospitals in Japan.
Data for laparoscopic nephrectomy were limited and only available for 50 cases. This limitation reflects the policy of the Japanese public medical insurance system, which did not cover laparoscopic nephrectomy before 2002. However, local control of RCC by laparoscopic nephrectomy is comparable with that achieved by open nephrectomy [21] and is thus believed to be a reasonable method. Therefore, the results of this study can be applied to localized RCC patients in current and future clinical settings.
Although Ficarra et al. reported recent improvement in the concordance between the original and reviewing pathologists regarding RCC HS (kappa = 0.43 from 1986 to 1997; 0.73 from 1998 to 2000) [5] , substantial discordance was identified in this study with regard to HS (9.1 %) and nuclear grade (78.9 %). This increased discordance reveals the importance of central pathological review, particularly for series that include cases from more than a decade ago.
The prognostic significance of HS after curative nephrectomy was defined by univariate analysis [6-9, 22, 23] . The results for our univariate analysis indicated survival was best for patients with the chromophobe subtype, followed by those with clear, papillary type 2, and unclassified subtypes; survival with papillary type 1 was almost equal to that with the clear subtype. However, whether HS is an independent prognostic factor remains under discussion. Leibovich et al. reported that HS was an independent predictor of outcome in a multivariate analysis of 3062 RCC patients from whom samples were collected between 1970 and 2003; in that study, all specimens were reviewed by a single pathologist [8] . Patard et al. reported that HS was not an independent prognostic factor in a multivariate analysis of 4204 RCC patients diagnosed between 1984 and 2001, but those authors described the lack of a central pathological review as the main limitation of their study [22] . Although Capitaneo et al. reported that HS was an independent predictor of cancer-specific mortality (P = 0.03), those authors found no improvement in accuracy when HS was added to other predictors [23] . Ficarra et al. reported that HS was not an independent predictor of outcome in multivariate analysis of 491 RCC patients from whom data were collected between 1986 and 2000, in which all specimens were reassigned by a single pathologist [5] . Amin et al. concluded that HS was not an independent predictor of outcome in a multivariate analysis of 405 RCC patients collected between 1968 and 1994, in which the final pathological review was performed by 3 pathologists [6] . Crepel et al. recently reported that HS was not a prognostic factor for use of partial nephrectomy to treat small RCC [24] . Furthermore, even the unclassified subtype was not proved to be a statistically independent survival factor [25] . Although Keegan et al. reported that the HS was predictive of survival, only the rare collecting duct and sarcomatoid HS of RCC were definite independent survival factors [26] . The merit of our study is use of a central pathological review in accordance with the current WHO classification and inclusion of RCC patients diagnosed between 1995 and 2000 with sufficient follow-up, indicating that it is among the most reliable RCC outcome studies in the era of cytokine treatment. In multivariate analysis of associations with OS, CSS, and RFS after potentially curative nephrectomy against local RCC in this study, HS was not found to be an independent prognostic factor even after the papillary subtype was further classified as type 1 or 2; in addition, survival analysis of rare HS, for example collecting duct carcinoma or sarcomatoid RCC was impossible because of the limited sample size. In contrast, tumor size, Fuhrman grade (excluding cases with the chromophobe subtype), and infiltration type had a much greater effect on survival after curative nephrectomy in this study.
Potential limitations of this study must be considered. Despite analysis of data from a total of 814 RCC patients with available clinical, and pathological evaluation data, sample size was apparently not sufficiently large to determine statistical differences in survival among patients with different HS, including collecting duct HS and sarcomatoid HS. Moreover, although patients with RCC were consecutively enrolled retrospectively, confirmation of the histopathological diagnosis of RCC in this study might have favored selection of patients with resectable tumors. Therefore, a potential selection bias might have existed against patients with late-stage and rapidly growing disease. Finally, although central pathological reviews were performed by 5 specialized pathologists, only 2 representative H&E slides were available per case, resulting in 94 undetermined HS cases.
Despite some limitations, this report indicates the true state of RCC outcomes via central pathological review near the year 2000. Although the RCC HS does not seem to be an independent prognostic factor after potentially curative nephrectomy, the prognostic significance of HS might increase after the emergence of such targeting agents as tyrosine-kinase inhibitors or mTOR inhibitors, because some of these agents are designed to block the carcinogenic signaling pathways of specific RCC HS and are, therefore, more effective for these specific HS. It will be interesting to compare the significance of HS in RCC outcomes in the era of targeting agents with these results.
In conclusion, we report some of the latest and most reliable data regarding the survival of RCC patients treated with curative nephrectomy. HS was not an independent prognostic factor of RCC, whereas tumor size, Fuhrman grade (excluding chromophobe subtype cases), and infiltration type had much greater effects on survival in the era of cytokine treatment. Discordance between the original and centrally reviewed pathological results regarding HS and nuclear grades indicated that a central pathological review conducted by experienced pathologists in accordance with updated histopathological classifications is essential in large-scale outcome studies.
